Drugs for HIV infection

Medical Letter on Drugs and Therapeutics

Volumn 39, Issue 1015, 1997, Pages 111-116

  Abramowicz, Mark ^f   Rizack, Martin A ^a   Goodstein, Donna ^f   Faucard, Amy ^f   Hansten, Philip D ^b   Steigbigel, Neal H ^c   Mukherjee, Sandip K ^d   Smoller, Jordan W ^e   Zuccotti, Gianna ^c   Aschenbrenner, Marianne ^f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DELAVIRDINE; DIARRHEA; DIDANOSINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; VIRUS REPLICATION; ZALCITABINE; ZIDOVUDINE;

EID: 1842413700     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. CCJ Carpenter et al, JAMA, 277:1962, 1997
2. JA Englund et al, N Engl J Med, 336:1704, 1997; CAESAR Coordinating Committee, Lancet, 349:1413, 1997
3. JA Englund et al, N Engl J Med, 336:1704, 1997; CAESAR Coordinating Committee, Lancet, 349:1413, 1997
4. Morbid Mortal Weekly Rep, 45:468, 1996; MH Katz and JL Gerberding, N Engl J Med, 336:1097, 1997
5. Morbid Mortal Weekly Rep, 45:468, 1996; MH Katz and JL Gerberding, N Engl J Med, 336:1097, 1997
6. EM Connor et al, N Engl J Med, 331:1173, 1994
7. R Pollard et al, Conf Retrovir Opportun Infect, 3:89, 1996; C Katlama et al, Conf Retrovir Opportun Infect, 4:206, 1997
8. R Pollard et al, Conf Retrovir Opportun Infect, 3:89, 1996; C Katlama et al, Conf Retrovir Opportun Infect, 4:206, 1997
9. S Staszewski et al, AIDS, 11:477, 1997
10. SM Hammer et al, N Engl J Med, 335:1081, 1996; Delta Coordinating Committee, Lancet, 348:283, 1996
11. SM Hammer et al, N Engl J Med, 335:1081, 1996; Delta Coordinating Committee, Lancet, 348:283, 1996
12. B Conway et al, AIDS, 10 suppl 2:S15, 1996; S Vella et al, Intersci Conf Antimicrob Agents Chemother, 37:abstract LB-7, 1997
13. B Conway et al, AIDS, 10 suppl 2:S15, 1996; S Vella et al, Intersci Conf Antimicrob Agents Chemother, 37:abstract LB-7, 1997
14. RT D'Aquila et al, Ann Intern Med, 124:1019, 1996
15. K Luzuriaga et al, N Engl J Med, 336:1343, 1997
16. M Harris et al, Intersci Conf Antimicrob Agents Chemother, 37:275, 1997
17. GH Friedland et al, Infect Dis Soc Am, 35:111, 1997
18. P Lorenzi et al, AIDS, 11:F95, 1997
19. B Cameron et al, Conf Retrovir Opportun Infect, 3:162, 1996
20. SM Hammer et al, N Engl J Med, 337:725, Sept 11, 1997
21. RM Gulick et al, N Engl J Med, 737:734, Sept 11, 1997
22. JB Kopp et al, Ann Intern Med, 127:119, July 15, 1997
23. L Pedneault, et al, Conf Retrovir Opportun Infect, 4:109, 1997
24. M Saag et al, Infect Dis Soc Am, 35:112, 1997